Demand for drugs like Ozempic could boost health insurers’ bottom lines, according to BofA. Insurers and the drug-industry middlemen they own stand to earn more as healthcare spending increases. Insurers’ membership could also swell if the drugs help people live longer. Loading Something is loading. Thanks for signing up! Access your favorite topics in a…